A

AIM ImmunoTech Inc
AMEX:AIM

Watchlist Manager
AIM ImmunoTech Inc
AMEX:AIM
Watchlist
Price: 1.18 USD -11.94% Market Closed
Market Cap: 3.4m USD

Operating Margin

-13 726.4%
Current
Improving
by 249.5%
vs 3-y average of -13 975.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-13 726.4%
=
Operating Income
$-16.6m
/
Revenue
$121k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-13 726.4%
=
Operating Income
$-16.6m
/
Revenue
$121k

Peer Comparison

Country Company Market Cap Operating
Margin
US
AIM ImmunoTech Inc
AMEX:AIM
3.4m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
377.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
156.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4rd
Based on 14 112 companies
4rd percentile
-13 726.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

AIM ImmunoTech Inc
Glance View

Market Cap
3.4m USD
Industry
Biotechnology

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The firm's products are Alferon N Injection and Ampligen. Alferon N Injection is a natural-source, glycosylated, multi-species alpha interferon product. Alferon is used for the treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Ampligen (rintatolimod), which is a drug of macromolecular RNA (ribonucleic acid) molecules, it is a sterile solution indicated for the treatment of severely debilitated patients with Chronic Fatigue Syndrome (CFS) who have been diagnosed for longer than one year. Ampligen is used in combination with checkpoint blockade therapies. Ampligen is also being used as a monotherapy to treat pancreatic cancer patients.

AIM Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-13 726.4%
=
Operating Income
$-16.6m
/
Revenue
$121k
What is AIM ImmunoTech Inc's current Operating Margin?

The current Operating Margin for AIM ImmunoTech Inc is -13 726.4%, which is above its 3-year median of -13 975.9%.

How has Operating Margin changed over time?

Over the last 3 years, AIM ImmunoTech Inc’s Operating Margin has decreased from -11 946.6% to -13 726.4%. During this period, it reached a low of -17 282.9% on Mar 31, 2024 and a high of -11 630.6% on Dec 31, 2024.

Back to Top